Chinese biotech dominance in R&D is increasing (MRK:NYSE)
Chinese biotech dominance in R&D is increasing (MRK:NYSE)


January 18, 2025 3:56 pm ETMerck & Co., Inc. (MRK) Stock, AZN StockGSK, NVS, RHHBYNVO, LLY, NVSEF, RHHBF, ABBV, GCVRZ, SMMT, HNSPF, AKESFBy: Dulan Lokuwithana, SA News Editor

narvikk/E+ via Getty Images

Against a backdrop of rising geopolitical tensions between the United States and China, there are signs of growing negotiating activity between Western pharmaceutical companies and Chinese biotechs, several research firms suggest.

Big pharma companies have licensed almost a third of their external molecules of Chinese origin.

By Admin

Leave a Reply

Your email address will not be published. Required fields are marked *